FDA approves much-debated Alzheimer's drug panned by experts

New Zealand Herald

07 Jun 2021 0 shares 1 views

FDA approves much-debated Alzheimer's drug panned by experts

New Zealand Herald

Published 07 Jun 2021

US government health officials on Monday (US time) approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow...

Full Article

How the new Alzheimer’s disease drug could influence future research

Upworthy 24 Jun 2021

The FDA’s controversial approval of a Biogen drug for Alzheimer’s disease could blunt future R&D, experts warn.

Stocks end mixed but Nasdaq powers to another record close
Proactive Investors 23 Jun 2021
US stocks mixed at mid-session as traders get cautious on risk
Proactive Investors 23 Jun 2021
Wall Street rises at the opening bell
Proactive Investors 23 Jun 2021
Many Alzheimer’s Experts Say Use of Aduhelm Should Be Sharply Limited
NYTimes.com 22 Jun 2021

More coverage

FDA officials asked to step down after contentious Alzheimer’s drug approval

Ars Technica 17 Jun 2021

Three experts resigned in protest. Watchdog says it's FDA brass that should leave.

FDA officials should resign over 'reckless' approval of Biogen Alzheimer’s drug, says US consumer rights group
Proactive Investors 16 Jun 2021
First patient set to receive controversial Biogen Alzheimer' s drug
MENAFN.com 16 Jun 2021
Three experts resign as FDA advisors over approval of Alzheimer’s drug
Ars Technica 11 Jun 2021
New Controversial Alzheimer's Drug Provides Hope, Says Patient
NPR 11 Jun 2021

FDA approves much-debated Alzheimer's drug panned by experts

FDA approves much-debated Alzheimer's drug panned by experts

You might like

Related news coverage

How the new Alzheimer’s disease drug could influence future research

Advertisement

More coverage

FDA officials asked to step down after contentious Alzheimer’s drug approval